Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

The DESTINY-Gastric04 study is comparing Enhertu (trastuzumab deruxtecan ... who have progressed on or after a trastuzumab-containing regimen. The interim results "demonstrated a statistically ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...

the FDA approved Enhertu in stomach cancer following prior treatment with a trastuzumab (Herceptin)-based regimen. That second-line nod was based on results from the phase 2 Destiny-Gastric01 ...

The authors of the study write in the Nature Medicine paper that, without a direct comparison between Enhertu and the Tukysa regimen, treatment selection for previously treated patients with ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

Enhertu is a HER2-directed DXd antibody-drug ... or PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. The Committee for Medicinal Products for Human ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in the ...

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday celebrated another approval of their cancer drug Enhertu. The Cambridge, England-based and Tokyo-based pharmaceutical ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LON:AZN) (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in ...